172 related articles for article (PubMed ID: 11455023)
1. Structural constraints affect the metabolism of 7-ethyl-10-[4-(1-piperidino)-1-piperidino]carbonyloxycamptothecin (CPT-11) by carboxylesterases.
Wadkins RM; Morton CL; Weeks JK; Oliver L; Wierdl M; Danks MK; Potter PM
Mol Pharmacol; 2001 Aug; 60(2):355-62. PubMed ID: 11455023
[TBL] [Abstract][Full Text] [Related]
2. Hydrolysis of irinotecan and its oxidative metabolites, 7-ethyl-10-[4-N-(5-aminopentanoic acid)-1-piperidino] carbonyloxycamptothecin and 7-ethyl-10-[4-(1-piperidino)-1-amino]-carbonyloxycamptothecin, by human carboxylesterases CES1A1, CES2, and a newly expressed carboxylesterase isoenzyme, CES3.
Sanghani SP; Quinney SK; Fredenburg TB; Davis WI; Murry DJ; Bosron WF
Drug Metab Dispos; 2004 May; 32(5):505-11. PubMed ID: 15100172
[TBL] [Abstract][Full Text] [Related]
3. Proficient metabolism of irinotecan by a human intestinal carboxylesterase.
Khanna R; Morton CL; Danks MK; Potter PM
Cancer Res; 2000 Sep; 60(17):4725-8. PubMed ID: 10987276
[TBL] [Abstract][Full Text] [Related]
4. Activation of a camptothecin prodrug by specific carboxylesterases as predicted by quantitative structure-activity relationship and molecular docking studies.
Yoon KJ; Krull EJ; Morton CL; Bornmann WG; Lee RE; Potter PM; Danks MK
Mol Cancer Ther; 2003 Nov; 2(11):1171-81. PubMed ID: 14617791
[TBL] [Abstract][Full Text] [Related]
5. Structural insights into CPT-11 activation by mammalian carboxylesterases.
Bencharit S; Morton CL; Howard-Williams EL; Danks MK; Potter PM; Redinbo MR
Nat Struct Biol; 2002 May; 9(5):337-42. PubMed ID: 11967565
[TBL] [Abstract][Full Text] [Related]
6. Comparison of activation of CPT-11 by rabbit and human carboxylesterases for use in enzyme/prodrug therapy.
Danks MK; Morton CL; Krull EJ; Cheshire PJ; Richmond LB; Naeve CW; Pawlik CA; Houghton PJ; Potter PM
Clin Cancer Res; 1999 Apr; 5(4):917-24. PubMed ID: 10213229
[TBL] [Abstract][Full Text] [Related]
7. Isolation and partial characterization of a cDNA encoding a rabbit liver carboxylesterase that activates the prodrug irinotecan (CPT-11).
Potter PM; Pawlik CA; Morton CL; Naeve CW; Danks MK
Cancer Res; 1998 Jun; 58(12):2646-51. PubMed ID: 9635592
[TBL] [Abstract][Full Text] [Related]
8. Overexpression of a rabbit liver carboxylesterase sensitizes human tumor cells to CPT-11.
Danks MK; Morton CL; Pawlik CA; Potter PM
Cancer Res; 1998 Jan; 58(1):20-2. PubMed ID: 9426050
[TBL] [Abstract][Full Text] [Related]
9. An improved human carboxylesterase for enzyme/prodrug therapy with CPT-11.
Wierdl M; Tsurkan L; Hyatt JL; Edwards CC; Hatfield MJ; Morton CL; Houghton PJ; Danks MK; Redinbo MR; Potter PM
Cancer Gene Ther; 2008 Mar; 15(3):183-92. PubMed ID: 18188187
[TBL] [Abstract][Full Text] [Related]
10. Molecular modeling of CPT-11 metabolism by carboxylesterases (CEs): use of pnb CE as a model.
Wierdl M; Morton CL; Nguyen NK; Redinbo MR; Potter PM
Biochemistry; 2004 Feb; 43(7):1874-82. PubMed ID: 14967028
[TBL] [Abstract][Full Text] [Related]
11. The crystal structure of the complex of the anticancer prodrug 7-ethyl-10-[4-(1-piperidino)-1-piperidino]-carbonyloxycamptothecin (CPT-11) with Torpedo californica acetylcholinesterase provides a molecular explanation for its cholinergic action.
Harel M; Hyatt JL; Brumshtein B; Morton CL; Yoon KJ; Wadkins RM; Silman I; Sussman JL; Potter PM
Mol Pharmacol; 2005 Jun; 67(6):1874-81. PubMed ID: 15772291
[TBL] [Abstract][Full Text] [Related]
12. Metabolic activation of CPT-11, 7-ethyl-10-[4-(1-piperidino)-1- piperidino]carbonyloxycamptothecin, a novel antitumor agent, by carboxylesterase.
Satoh T; Hosokawa M; Atsumi R; Suzuki W; Hakusui H; Nagai E
Biol Pharm Bull; 1994 May; 17(5):662-4. PubMed ID: 7920428
[TBL] [Abstract][Full Text] [Related]
13. Conversion of the CPT-11 metabolite APC to SN-38 by rabbit liver carboxylesterase.
Guichard SM; Morton CL; Krull EJ; Stewart CF; Danks MK; Potter PM
Clin Cancer Res; 1998 Dec; 4(12):3089-94. PubMed ID: 9865925
[TBL] [Abstract][Full Text] [Related]
14. Identification and activities of human carboxylesterases for the activation of CPT-11, a clinically approved anticancer drug.
Senter PD; Beam KS; Mixan B; Wahl AF
Bioconjug Chem; 2001; 12(6):1074-80. PubMed ID: 11716702
[TBL] [Abstract][Full Text] [Related]
15. Mouse liver and kidney carboxylesterase (M-LK) rapidly hydrolyzes antitumor prodrug irinotecan and the N-terminal three quarter sequence determines substrate selectivity.
Xie M; Yang D; Wu M; Xue B; Yan B
Drug Metab Dispos; 2003 Jan; 31(1):21-7. PubMed ID: 12485949
[TBL] [Abstract][Full Text] [Related]
16. The role of rat serum carboxylesterase in the activation of paclitaxel and camptothecin prodrugs.
Senter PD; Marquardt H; Thomas BA; Hammock BD; Frank IS; Svensson HP
Cancer Res; 1996 Apr; 56(7):1471-4. PubMed ID: 8603386
[TBL] [Abstract][Full Text] [Related]
17. CPT-11 converting enzyme from rat serum: purification and some properties.
Tsuji T; Kaneda N; Kado K; Yokokura T; Yoshimoto T; Tsuru D
J Pharmacobiodyn; 1991 Jun; 14(6):341-9. PubMed ID: 1783980
[TBL] [Abstract][Full Text] [Related]
18. Isolation and characterization of a cDNA encoding a horse liver butyrylcholinesterase: evidence for CPT-11 drug activation.
Wierdl M; Morton CL; Danks MK; Potter PM
Biochem Pharmacol; 2000 Apr; 59(7):773-81. PubMed ID: 10718335
[TBL] [Abstract][Full Text] [Related]
19. Characterization of CPT-11 hydrolysis by human liver carboxylesterase isoforms hCE-1 and hCE-2.
Humerickhouse R; Lohrbach K; Li L; Bosron WF; Dolan ME
Cancer Res; 2000 Mar; 60(5):1189-92. PubMed ID: 10728672
[TBL] [Abstract][Full Text] [Related]
20. Sensitization of human tumor cells to CPT-11 via adenoviral-mediated delivery of a rabbit liver carboxylesterase.
Wierdl M; Morton CL; Weeks JK; Danks MK; Harris LC; Potter PM
Cancer Res; 2001 Jul; 61(13):5078-82. PubMed ID: 11431344
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]